BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7585732)

  • 1. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors.
    Weikel W; Brumm C; Wilkens C; Beck T; Knapstein PG
    Cancer Detect Prev; 1995; 19(5):446-50. PubMed ID: 7585732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of proliferative index (PCNA reactivity and Ki-67 reactivity) in primary breast carcinoma with hormone status, lymph node status, and disease-free survival.
    Magno WB; Hirschfield L; Bhuiya T; Harrison G; Mir R
    Conn Med; 1992 Dec; 56(12):667-9. PubMed ID: 1363223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Determination of the growth fraction using monoclonal antibody Ki-67 in breast cancers].
    Lellé RJ; Heidenreich W; Borsi C; Stauch G; Gerdes J
    J Gynecol Obstet Biol Reprod (Paris); 1988; 17(4):485-9. PubMed ID: 3209828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ki 67 growth fraction in carcinomas and benign lesions of the breast].
    Kunz J; Schmidt A
    Zentralbl Pathol; 1993 Aug; 139(3):201-5. PubMed ID: 8218121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
    Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
    Dolled-Filhart M; Camp RL; Kowalski DP; Smith BL; Rimm DL
    Clin Cancer Res; 2003 Feb; 9(2):594-600. PubMed ID: 12576423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
    Brown RW; Allred CD; Clark GM; Osborne CK; Hilsenbeck SG
    Clin Cancer Res; 1996 Mar; 2(3):585-92. PubMed ID: 9816207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
    Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer.
    Miyake M; Nakano K; Itoi SI; Koh T; Taki T
    Cancer Res; 1996 Mar; 56(6):1244-9. PubMed ID: 8640807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of tumor biological prognostic factors in adjuvant therapy of node-negative breast cancer].
    Jänicke F
    Zentralbl Gynakol; 1994; 116(8):449-55. PubMed ID: 7941813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer.
    Siitonen SM; Kallioniemi OP; Isola JJ
    Am J Pathol; 1993 Apr; 142(4):1081-9. PubMed ID: 7682759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.